ArriVent BioPharma Announces Program Update for FURVENT Trial
ArriVent BioPharma announced a program update from the Phase 3 FURVENT trial evaluating firmonertinib in first-line EGFR Exon 20 insertion mutant NSCLC.
ArriVent BioPharma announced a program update from the Phase 3 FURVENT trial evaluating firmonertinib in first-line EGFR Exon 20 insertion mutant NSCLC.